Evolus Inc (EOLS) — Titan Protect Analysis

EOLS

Evolus Inc

Healthcare · ·

$6.67

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$399M

Total market value of the company

Trailing P/E

N/A

Forward P/E

22.71

Based on estimated future earnings — lower means cheaper

Rev Growth

+6.7%

Year-over-year revenue change

Profit Margin

-14.4%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$14.00

+110% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 6 analysts covering this stock

About Evolus Inc

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was

https://www.evolus.com

Country: United States Employees: 350 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.193

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0276

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.373

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-28.9%

Historical annualised return based on price data

Max Drawdown

-77.5%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.29

Moves slightly more than the broader market

52W High

$10.62

37% below the year high

52W Low

$3.86

73% above the year low

Avg Volume

1,120,542

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.66

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

66.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-9.4%

Profit from core operations before interest and tax

Free Cash Flow

$-23,226,376

Negative — the business is spending more than it generates

Revenue (TTM)

$302M

Total revenue over the last 12 months

Net Income

$-43,423,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$20.00

Target Median

$14.00

Target Low

$10.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go